Prashant Nagre appointed as MD of Fermenta Biotech

Strategic decision to fuel next phase of growth for the company
Read Article

Krishna Datla, Promoter and MD of Fermenta Biotech announced the appointment of CEO, Prashant Nagre, as the new MD with effect from May 9, 2021. Datla will continue as a Board member and the Executive Vice Chairman.

Prashant Nagre joined FBL in 2010 as the COO and in two years, was elevated to the position of CEO. Since then, he has led corporate strategy, business operations and demand-driven innovation for FBL’s three business verticals viz., Vitamin D and other APIs, Integrated Biotechnology and Environmental Solutions. “Under the leadership of Datla, during Nagre’s tenure, FBL has expanded from a solely domestic-focused business to a global vitamin player, with more than 70 per cent of revenues now arising from exports. Nagre will also be responsible for steering the company’s efforts to foray into the nutrition segment by developing a future-ready organisation with a value-added portfolio, informed the company through a statement.

Datla commented, “Prashant has led various transformational milestones for accelerating the organisation’s progress, and we have immense faith in his leadership. As the company is evolving into a global entity, we think, Prashant is aptly suited to achieve our strategic vision. Prashant’s track record at FBL coupled with his vast professional experience will be instrumental in driving the next phase of growth. We welcome Prashant on the Board and look forward to taking our success to newer heights.”

FBLFermenta BiotechKrishna Datlaleadership appointmentPrashant Nagre
Comments (0)
Add Comment